

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Romosozumab for treating severe osteoporosis [ID3936]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes.

Romosozumab is indicated only in postmenopausal women. Such an indication excludes men and could be considered an equality issue.

Second, it was highlighted that an optimised recommendation may exclude patients at high or very high risk of fracture from more effective therapies. It is unclear if there are particular characteristics within this group that could amount of an equalities consideration.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Exclusion of men within previous NCIE recommendation within osteoporosis has been raised as an equalities issue. Therefore, the NICE committee will need to address this equalities issue within the appraisal.

If an optimised recommendation is made in the context of risk of fracture, the committee will need to consider if this recommendation potentially discriminates against any particular groups.

3. Has any change to the draft scope been agreed to highlight potential

equality issues?
No, as men are currently outside of the romosozumab marketing authorisation.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No additional stakeholders have been identified or changes made to the matrix

Approved by Associate Director (name): Henry Edwards

Date: 20/04/21